DRUG trades 234.6% below Wall Street's consensus target of $171.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DRUG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 17, 2026, Bright Minds Biosciences Inc. (DRUG) has a Wall Street consensus price target of $171.67, based on estimates from 4 covering analysts. With the stock currently trading at $51.30, this represents a potential upside of +234.6%. The company has a market capitalization of $502M.
Analyst price targets range from a low of $145.00 to a high of $220.00, representing a 44% spread in expectations. The median target of $150.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DRUG trades at a trailing P/E of -40.8x. Analysts expect EPS to grow -58.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CMPSCOMPASS Pathways plc | $1.5B | $10.75 | $18.63 | +73.3% | Buy | — | 15 |
 ATAIAtai Beckley Inc. | $2.7B | $7.35 | $7.69 | +4.6% | Hold | — | 8 |
 MNMDMind Medicine (MindMed) Inc. | $3.2B | $42.79 | $20.00 | -53.3% | Buy | — | 1 |
 CYBNCybin Inc. | $1.1B | $6.09 | — | — | Buy | — | 4 |
 NRXPNRx Pharmaceuticals, Inc. | $45M | $2.60 | — | — | — | — | — |
 ACADACADIA Pharmaceuticals Inc. | $3.3B | $19.12 | $29.95 | +56.6% | Buy | 30.7x | 37 |
 AXSMAxsome Therapeutics, Inc. | $8.1B | $157.14 | $283.00 | +80.1% | Buy | — | 27 |
 INVAInnoviva, Inc. | $1.5B | $20.78 | $38.00 | +82.9% | Buy | 8.6x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $6.7B | $241.76 | $611.69 | +153.0% | Buy | — | 18 |
 LLYEli Lilly and Company | $1.2T | $1257.03 | $1345.80 | +7.1% | Buy | 35.9x | 45 |
Quick answers to the most common questions about buying DRUG stock.
The consensus Wall Street price target for DRUG is $171.67, representing 234.6% upside from the current price of $51.3. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DRUG has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $171.67 implies 234.6% upside from current levels.
DRUG's current price is $51.3 with a consensus target of $171.67 (234.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $220 for DRUG, while the most conservative target is $145. The consensus of $171.67 represents the median expectation. These targets typically reflect 12-month expectations.
DRUG is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DRUG stock forecast based on 4 Wall Street analysts shows a consensus price target of $171.67, with estimates ranging from $145 (bear case) to $220 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DRUG, with a "Buy" consensus rating and $171.67 price target (234.6% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DRUG analyst price targets range from $145 to $220, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $171.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.